MDT

96.1

-0.44%↓

137.81

-0.48%↓

VEEV

224.76

+0.38%↑

HQY

92.67

-0.47%↓

PHR.US

16.99

-0.18%↓

MDT

96.1

-0.44%↓

137.81

-0.48%↓

VEEV

224.76

+0.38%↑

HQY

92.67

-0.47%↓

PHR.US

16.99

-0.18%↓

MDT

96.1

-0.44%↓

137.81

-0.48%↓

VEEV

224.76

+0.38%↑

HQY

92.67

-0.47%↓

PHR.US

16.99

-0.18%↓

MDT

96.1

-0.44%↓

137.81

-0.48%↓

VEEV

224.76

+0.38%↑

HQY

92.67

-0.47%↓

PHR.US

16.99

-0.18%↓

MDT

96.1

-0.44%↓

137.81

-0.48%↓

VEEV

224.76

+0.38%↑

HQY

92.67

-0.47%↓

PHR.US

16.99

-0.18%↓

Kodu・Aktsiate loetelu・Abeona Therapeutics Inc

Abeona Therapeutics Inc

Suletud

5.37 -1.47

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

5.2

Max

5.45

Põhinäitajad
By Trading Economics
P/E Sektori keskmine	4.224 78.892
Töötajad	136

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+335.78% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	19. märts 2026

Turustatistika
By TradingEconomics
Turukapital	21M 245M
Eelmine avamishind	6.84
Eelmine sulgemishind	5.37

Abeona Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

12. nov 2025, 19:31 UTC

Tulu

Suurimad hinnamuutused turgudel

Abeona Therapeutics Shares Soar on Higher Demand for Zevaskyn

Võrdlus sarnastega

Hinnamuutus

Abeona Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

335.78% tõus

12 kuu keskmine prognoos

Keskmine 23.75 USD 335.78%

Kõrge 27.5 USD

Madal 20 USD

Põhineb 3 Wall Streeti analüütiku instrumendi Abeona Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

3 ratings

Osta

Hoia

Müü

Põhineb 3 analüütiku instrumendi Abeona Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Finantsandmed

Ettevõttest Abeona Therapeutics Inc

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. is headquartered in Cleveland, Ohio.